BIOMAT Database Logo BIOMAT Database Logo

Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. 1998

M N Levine, and V H Bramwell, and K I Pritchard, and B D Norris, and L E Shepherd, and H Abu-Zahra, and B Findlay, and D Warr, and D Bowman, and J Myles, and A Arnold, and T Vandenberg, and R MacKenzie, and J Robert, and J Ottaway, and M Burnell, and C K Williams, and D Tu
Hamilton Regional Cancer Centre, McMaster University, ON, Canada.

OBJECTIVE To determine the relative efficacy of an intensive cyclophosphamide, epirubicin, and fluorouracil (CEF) adjuvant chemotherapy regimen compared with cyclophosphamide, methotrexate, and fluorouracil (CMF) in node-positive breast cancer. METHODS Premenopausal women with node-positive breast cancer were randomly allocated to receive either cyclophosphamide 100 mg/m2 orally days 1 through 14; methotrexate 40 mg/m2 intravenously (i.v.) days 1 and 8; and fluorouracil 600 mg/m2 i.v. days 1 and 8 or cyclophosphomide 75 mg/m2 orally days 1 through 14; epirubicin 60 mg/m2 i.v. days 1 and 8; and fluorouracil 500 mg/m2 i.v. days 1 and 8. Each cycle was administered monthly for 6 months. Patients administered CEF received antibiotic prophylaxis with cotrimoxazole two tablets twice a day for the duration of chemotherapy. RESULTS The median follow-up was 59 months. One hundred sixty-nine of the 359 CMF patients developed recurrence compared with 132 of the 351 CEF patients. The corresponding 5-year relapse-free survival rates were 53% and 63%, respectively (P = .009). One hundred seven CMF patients died compared with 85 CEF patients. The corresponding 5-year actuarial survival rates were 70% and 77%, respectively (P = .03). The rate of hospitalization for febrile neutropenia was 1.1% in the CMF group compared with 8.5% in the CEF group. There was one case of congestive heart failure in a patient who received CMF compared with none in the CEF group. Acute leukemia occurred in five patients in the CEF group. CONCLUSIONS The results of this trial show the superiority of CEF over CMF in terms of both disease-free and overall survival in premenopausal women with axillary node-positive breast cancer.

UI MeSH Term Description Entries
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy

Related Publications

M N Levine, and V H Bramwell, and K I Pritchard, and B D Norris, and L E Shepherd, and H Abu-Zahra, and B Findlay, and D Warr, and D Bowman, and J Myles, and A Arnold, and T Vandenberg, and R MacKenzie, and J Robert, and J Ottaway, and M Burnell, and C K Williams, and D Tu
Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan.
July 2010, Breast cancer (Tokyo, Japan),
M N Levine, and V H Bramwell, and K I Pritchard, and B D Norris, and L E Shepherd, and H Abu-Zahra, and B Findlay, and D Warr, and D Bowman, and J Myles, and A Arnold, and T Vandenberg, and R MacKenzie, and J Robert, and J Ottaway, and M Burnell, and C K Williams, and D Tu
Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group.
January 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
M N Levine, and V H Bramwell, and K I Pritchard, and B D Norris, and L E Shepherd, and H Abu-Zahra, and B Findlay, and D Warr, and D Bowman, and J Myles, and A Arnold, and T Vandenberg, and R MacKenzie, and J Robert, and J Ottaway, and M Burnell, and C K Williams, and D Tu
Q-TWiST analysis of cyclophosphamide, epirubicin, fluorouracil versus cyclophosphamide, methotrexate, fluorouracil treatment for premenopausal women with node-positive breast cancer.
January 2005, PharmacoEconomics,
M N Levine, and V H Bramwell, and K I Pritchard, and B D Norris, and L E Shepherd, and H Abu-Zahra, and B Findlay, and D Warr, and D Bowman, and J Myles, and A Arnold, and T Vandenberg, and R MacKenzie, and J Robert, and J Ottaway, and M Burnell, and C K Williams, and D Tu
Design and rationale of a randomised comparison of cyclophosphamide, methotrexate and fluorouracil vs fluorouracil, epirubicin and cyclophosphamide in node-positive premenopausal women with operable breast cancer. A trial of the International Collaborative Cancer Group (ICCG).
January 1993, Drugs,
M N Levine, and V H Bramwell, and K I Pritchard, and B D Norris, and L E Shepherd, and H Abu-Zahra, and B Findlay, and D Warr, and D Bowman, and J Myles, and A Arnold, and T Vandenberg, and R MacKenzie, and J Robert, and J Ottaway, and M Burnell, and C K Williams, and D Tu
Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
December 2000, Cancer,
M N Levine, and V H Bramwell, and K I Pritchard, and B D Norris, and L E Shepherd, and H Abu-Zahra, and B Findlay, and D Warr, and D Bowman, and J Myles, and A Arnold, and T Vandenberg, and R MacKenzie, and J Robert, and J Ottaway, and M Burnell, and C K Williams, and D Tu
A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada--Clinical Trials Group Trial, MA.12).
February 2010, Annals of oncology : official journal of the European Society for Medical Oncology,
M N Levine, and V H Bramwell, and K I Pritchard, and B D Norris, and L E Shepherd, and H Abu-Zahra, and B Findlay, and D Warr, and D Bowman, and J Myles, and A Arnold, and T Vandenberg, and R MacKenzie, and J Robert, and J Ottaway, and M Burnell, and C K Williams, and D Tu
Randomized clinical trial of adjuvant fluorouracil, epirubicin, and cyclophosphamide chemotherapy for patients with fast-proliferating, node-negative breast cancer.
October 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
M N Levine, and V H Bramwell, and K I Pritchard, and B D Norris, and L E Shepherd, and H Abu-Zahra, and B Findlay, and D Warr, and D Bowman, and J Myles, and A Arnold, and T Vandenberg, and R MacKenzie, and J Robert, and J Ottaway, and M Burnell, and C K Williams, and D Tu
Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer.
June 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
M N Levine, and V H Bramwell, and K I Pritchard, and B D Norris, and L E Shepherd, and H Abu-Zahra, and B Findlay, and D Warr, and D Bowman, and J Myles, and A Arnold, and T Vandenberg, and R MacKenzie, and J Robert, and J Ottaway, and M Burnell, and C K Williams, and D Tu
Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer.
November 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
M N Levine, and V H Bramwell, and K I Pritchard, and B D Norris, and L E Shepherd, and H Abu-Zahra, and B Findlay, and D Warr, and D Bowman, and J Myles, and A Arnold, and T Vandenberg, and R MacKenzie, and J Robert, and J Ottaway, and M Burnell, and C K Williams, and D Tu
Meta-analysis of adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy in postmenopausal women with estrogen receptor-positive, node-positive breast cancer.
July 2001, Clinical breast cancer,
Copied contents to your clipboard!